Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 56 | 84 | 145 | 115 | 43 |
| Accounts receivable | 334 | -165 | -223 | 37 | -1 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | 2,320 | 319 |
| Other Working Capital | 657 | 839 | -240 | 2,115 | 430 |
| Other Operating Activity | -20,547 | -17,598 | -10,977 | -22,372 | -9,060 |
| Operating Cash Flow | $-19,499 | $-16,841 | $-11,296 | $-17,784 | $-8,269 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | 0 | -3 | -21 | -3 |
| Purchase Sale Intangibles | 101 | 59 | -136 | 0 | -42 |
| Other Investing Activity | 101 | 59 | 0 | 0 | 0 |
| Investing Cash Flow | $101 | $59 | $-139 | $-21 | $-45 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -101 | -101 | -101 | -76 | N/A |
| Common Stock Issued | 16,885 | 23,012 | 0 | 19,763 | 18,902 |
| Other Financing Activity | 6,980 | -216 | 867 | 2,954 | 712 |
| Financing Cash Flow | $23,764 | $22,695 | $766 | $22,641 | $19,613 |
| Exchange Rate Effect | 436 | -305 | -124 | 687 | 31 |
| Beginning Cash Position | 17,267 | 11,660 | 22,452 | 16,929 | 5,599 |
| End Cash Position | 22,070 | 17,267 | 11,660 | 22,452 | 16,929 |
| Net Cash Flow | $4,366 | $5,913 | $-10,668 | $4,836 | $11,299 |
| Free Cash Flow | |||||
| Operating Cash Flow | -19,499 | -16,841 | -11,296 | -17,784 | -8,269 |
| Capital Expenditure | N/A | N/A | -141 | -21 | -45 |
| Free Cash Flow | -19,499 | -16,841 | -11,437 | -17,805 | -8,314 |